Hemab Therapeutics Holdings, Inc. (COAG)
Last updated: 2026-10-21 07:12:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
Hemab Therapeutics Holdings, Inc. (COAG) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $34.16, with a market capitalization of $1.50B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $23.00 to $55.42. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$1.50B | |
$32.16 | |
$55.42 | |
$23.00 | |
$32.09 | |
334.45K | |
464.33K | |
-- | |
$55.42 | |
$23.00 | |
-- | |
-- |
Hemab Therapeutics Holdings, Inc. (COAG) Latest Closing Stock Price
Hemab Therapeutics Holdings, Inc. (COAG) last closed at $32.09 as of 2026-10-20 23:31:00, unchanged from the previous close of $32.09.
During the latest regular trading session, COAG traded between $23.00 and $55.42, with a volume of 334.45K shares. The closing price was near the lower end and near the middle of its 52-week range.
Hemab Therapeutics Holdings, Inc. (COAG) 7-Day Stock Price Change
Over the past seven days, Hemab Therapeutics Holdings, Inc. (COAG) moved from $30.39 to $34.16, representing a gain of 12.40% ($3.77).
The stock traded between $29.01 and $34.53 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 340.60 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
COAG 52-Week Price Position
Position in Range: 34.4%
COAG is currently trading at $34.16, placing it 34.4% of the way from its 52-week low of $23.00 to its 52-week high of $55.42. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Hemab Therapeutics Holdings, Inc. (COAG)?
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
Hemab Therapeutics Holdings, Inc. Information
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Exchange | NASDAQ |
| Company Website |
How to Buy Hemab Therapeutics Holdings, Inc. (COAG) Stock on MEXC
Eligible investors can buy real shares of Hemab Therapeutics Holdings, Inc. (COAG) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Hemab Therapeutics Holdings, Inc. (COAG) stock price today?
2.Is COAG stock going up or down today?
3.What is COAG pre-market price?
4.What is COAG after-hours price?
5.Is COAG stock trading now?
6.Where does COAG sit relative to its 52-week high and low?
7.What sector is Hemab Therapeutics Holdings, Inc. in?
8.What is Hemab Therapeutics Holdings, Inc.'s market capitalization and where is it listed?
9.How is COAG valued in terms of P/E ratio and EPS?
10.Does Hemab Therapeutics Holdings, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
COAG Stock Calculator
Estimate the value between COAG shares and USD.
COAG Shares to USD
1.00 COAG shares = 34.157 USD
Calculations are estimates based on the latest available price and are for reference only.


